Discovery of small molecule inhibitors through pharmacophore modeling, molecular docking, molecular dynamics simulation and experimental validation against myeloid cell leukemia-1 (Mcl-1)

References

• Akgul, C. (2009). Mcl-1 is a potential therapeutic target in multiple types of cancer. Cellular and Molecular Life Sciences, 66(8), 1326–1336. doi:10.1007/s00018-008-8637-6
   PubMed Web of Science ®Google Scholar
• Bae, J., Leo, C. P., Hsu, S. Y., & Hsueh, A. J. (2000). MCL-1S, a splicing variant of the antiapoptotic BCL-2 family member MCL-1, encodes a proapoptotic protein possessing only the BH3 domain. Journal of Biological Chemistry, 275(33), 25255–25261. doi:10.1074/jbc.M909826199
   PubMed Web of Science ®Google Scholar
• Bingle, C. D., Craig, R. W., Swales, B. M., Singleton, V., Zhou, P., & Whyte, M. K. (2000). Exon skipping in Mcl-1 results in a bcl-2 homology domain 3 only gene product that promotes cell death. Journal of Biological Chemistry, 275(29), 22136–22146. doi:10.1074/jbc.M909572199
   PubMed Web of Science ®Google Scholar
• Day, C. L., Chen, L., Richardson, S. J., Harrison, P. J., Huang, D. C., & Hinds, M. G. (2005). Solution structure of prosurvival Mcl-1 and characterization of its binding by proapoptotic BH3-only ligands. Journal of Biological Chemistry, 280(6), 4738–4744. doi:10.1074/jbc.M411434200
   PubMed Web of Science ®Google Scholar
• Fire, E., Gulla, S. V., Grant, R. A., & Keating, A. E. (2010). Mcl-1-Bim complexes accommodate surprising point mutations via minor structural changes. Protein Science, 19(3), 507–519. doi:10.1002/pro.329
   PubMed Web of Science ®Google Scholar
• Florean, C., Kim, K. R., Schnekenburger, M., Kim, H. J., Moriou, C., Debitus, C., Dicato, M., Al-Mourabit, A., Han, B.W., & Diederich, M. (2018). Synergistic AML Cell death induction by marine Cytotoxin (+)-1(R), 6(S), 1’(R), 6’(S), 11(R), 17(S)-Fistularin-3 and Bcl-2 inhibitor venetoclax. Marine Drugs, 16(12), 518. doi:10.3390/md16120518
   Web of Science ®Google Scholar
• Foight, G. W., Ryan, J. A., Gulla, S. V., Letai, A., & Keating, A. E. (2014). Designed BH3 peptides with high affinity and specificity for targeting Mcl-1 in cells. ACS Chemical Biology, 9(9), 1962–1968. doi:10.1021/cb500340w
   PubMed Web of Science ®Google Scholar
• Friberg, A., Vigil, D., Zhao, B., Daniels, R. N., Burke, J. P., Garcia-Barrantes, P. M., Camper, D., Chauder, B. A., Lee, T., Olejniczak, E. T., & Fesik, S. W. (2013). Discovery of potent myeloid cell leukemia 1 (Mcl-1) inhibitors using fragment-based methods and structure-based design. Journal of Medicinal Chemistry, 56(1), 15–30. doi:10.1021/jm301448p
   PubMed Web of Science ®Google Scholar
• Gao, Y., Wang, H., Wang, J., & Cheng, M. (2019). In silico studies on p21-activated kinase 4 inhibitors: Comprehensive application of 3D-QSAR analysis, molecular docking, molecular dynamics simulations, and MM-GBSA calculation. Journal of Biomolecular Structure and Dynamics, 37. doi:10.1080/07391102.2019.1673823
   Google Scholar
• Glantz-Gashai, Y., Meirson, T., Reuveni, E., & Samson, A. O. (2017). Virtual screening for potential inhibitors of Mcl-1 conformations sampled by normal modes, molecular dynamics, and nuclear magnetic resonance. Drug Design, Development and Therapy, 11, 1803–1813. doi:10.2147/DDDT.S133127
   PubMed Web of Science ®Google Scholar
• Goodwin, C. M., Rossanese, O. W., Olejniczak, E. T., & Fesik, S. W. (2015). Myeloid cell leukemia-1 is an important apoptotic survival factor in triple-negative breast cancer. Cell Death & Differentiation, 22(12), 2098–2106. doi:10.1038/cdd.2015.73
   PubMed Web of Science ®Google Scholar
• Gu, X., Wang, Y., Wang, M., Wang, J., & Li, N. (2019). Computational investigation of imidazopyridine analogs as protein kinase B (Akt1) allosteric inhibitors by using 3D-QSAR, molecular docking and molecular dynamics simulations. Journal of Biomolecular Structure and Dynamics, 37. doi:10.1080/07391102.2019.1705185
   Google Scholar
• Jafarlou, M., Shanehbandi, D., Dehghan, P., Mansoori, B., Othman, F., & Baradaran, B. (2017). Enhancement of chemosensitivity by simultaneously silencing of Mcl-1 and Survivin genes using small interfering RNA in human myelomonocytic leukaemia. Artificial Cells, Nanomedicine, and Biotechnology, 46(8), 1–1798. doi:10.1080/21691401.2017.1392969
   Web of Science ®Google Scholar
• Kotschy, A., Szlavik, Z., Murray, J., Davidson, J., Maragno, A. L., Le Toumelin-Braizat, G., Chanrion, M., Kelly, G. L., Gong, J.-N., Moujalled, D. M., Bruno, A., Csekei, M., Paczal, A., Szabo, Z. B., Sipos, S., Radics, G., Proszenyak, A., Balint, B., Ondi, L., … Geneste, O. (2016). The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models. Nature, 538(7626), 477–482. doi:10.1038/nature19830
   PubMed Web of Science ®Google Scholar
• Lee, T., Christov, P. P., Shaw, S., Tarr, J. C., Zhao, B., Veerasamy, N., Jeon, K. O., Mills, J. J., Bian, Z., Sensintaffar, J. L., Arnold, A. L., Fogarty, S. A., Perry, E., Ramsey, H. E., Cook, R. S., Hollingshead, M., Davis Millin, M., Lee, K-m., Koss, B., … Fesik, S. W. (2019). Discovery of potent myeloid cell Leukemia-1 (Mcl-1) inhibitors that demonstrate in vivo activity in mouse xenograft models of human cancer. Journal of Medicinal Chemistry, 62(8), 3971–3988. doi:10.1021/acs.jmedchem.8b01991
   PubMed Web of Science ®Google Scholar
• Li, F., Wang, H., Wang, Y., Feng, S., Hu, B., Zhang, X., Wang, J., Li, W., & Cheng, M. (2019). Computational investigation reveals Picrasidine C as selective PPARα lead: Binding pattern, selectivity mechanism and ADME/tox profile. Journal of Biomolecular Structure and Dynamics, 37. doi:10.1080/07391102.2019.1699861
   Google Scholar
• Liu, Q., Moldoveanu, T., Sprules, T., Matta-Camacho, E., Mansur-Azzam, N., & Gehring, K. (2010). Apoptotic regulation by MCL-1 through heterodimerization. Journal of Biological Chemistry, 285(25), 19615–19624. doi:10.1074/jbc.M110.105452
   PubMed Web of Science ®Google Scholar
• Pan, Z., Wang, Y., Gu, X., Wang, J., & Cheng, M. (2019). Refined homology model of cytochrome bcc complex B subunit for virtual screening of potential anti-tuberculosis agents. Journal of Biomolecular Structure and Dynamics, 37. doi:10.1080/07391102.2019.1688196
   Google Scholar
• Roy, K., Chakraborty, P., Mitra, I., Ojha, P. K., Kar, S., & Das, R. N. (2013). Some case studies on application of “r(m)2” metrics for judging quality of quantitative structure-activity relationship predictions: Emphasis on scaling of response data. Journal of Computational Chemistry, 34(12), 1071–1082. doi:10.1002/jcc.23231
   PubMed Web of Science ®Google Scholar
• Shaw, S., Bian, Z., Zhao, B., Tarr, J. C., Veerasamy, N., Jeon, K. O., Belmar, J., Arnold, A. L., Fogarty, S. A., Perry, E., Sensintaffar, J. L., Camper, D. V., Rossanese, O. W., Lee, T., Olejniczak, E. T., & Fesik, S. W. (2018). Optimization of potent and selective tricyclic indole diazepinone myeloid cell Leukemia-1 inhibitors using structure-based design. Journal of Medicinal Chemistry, 61(6), 2410–2421. doi:10.1021/acs.jmedchem.7b01155
   PubMed Web of Science ®Google Scholar
• Su, Y., Song, P., Wang, H., Hu, B., Wang, J., & Cheng, M.-S. (2019). Precise design of highly isoform-selective p21-activated kinase 4 inhibitors: Computational insights into the selectivity mechanism through molecular dynamics simulation and binding free energy calculation. Journal of Biomolecular Structure and Dynamics, 37. doi:10.1080/07391102.2019.1664330
   PubMed Web of Science ®Google Scholar
• Timucin, A. C., Basaga, H., & Kutuk, O. (2019). Selective targeting of antiapoptotic BCL-2 proteins in cancer. Medicinal Research Reviews, 39(1), 146–175. doi:10.1002/med.21516
   PubMed Web of Science ®Google Scholar
• Wakui, N., Yoshino, R., Yasuo, N., Ohue, M., & Sekijima, M. (2018). Exploring the selectivity of inhibitor complexes with Bcl-2 and Bcl-XL: A molecular dynamics simulation approach. Journal of Molecular Graphics and Modelling, 79, 166–174. doi:10.1016/j.jmgm.2017.11.011
   PubMed Web of Science ®Google Scholar
• Wang, Y., Feng, S., Gao, H., & Wang, J. (2020). Computational investigations of gram-negative bacteria phosphopantetheine adenylyltransferase inhibitors using 3D-QSAR, molecular docking and molecular dynamic simulations. Journal of Biomolecular Structure and Dynamics, 38(5), 1435–1447. doi:10.1080/07391102.2019.1608305
   PubMed Web of Science ®Google Scholar
• Young, A. I., Timpson, P., Gallego-Ortega, D., Ormandy, C. J., & Oakes, S. R. (2018). Myeloid cell leukemia 1 (MCL-1), an unexpected modulator of protein kinase signaling during invasion. Cell Adhesion & Migration, 12(6), 513–523. doi:10.1080/19336918.2017.1393591
   PubMed Web of Science ®Google Scholar
• Yousuf, Z., Iman, K., Iftikhar, N., & Mirza, M. U. (2017). Structure-based virtual screening and molecular docking for the identification of potential multi-targeted inhibitors against breast cancer. Breast Cancer: Targets and Therapy, 9, 447–459. doi:10.2147/BCTT.S132074
   PubMed Web of Science ®Google Scholar
• Zhang, X., Yan, J., Wang, H., Wang, Y., Wang, J., & Zhao, D. (2020). Molecular docking, 3D-QSAR, and molecular dynamics simulations of thieno[3,2-b]pyrrole derivatives against anticancer targets of KDM1A/LSD1. Journal of Biomolecular Structure and Dynamics, 38. doi:10.1080/07391102.2020.1726819
   Web of Science ®Google Scholar
• Zhao, B., Arnold, A. L., Coronel, M. A., Lee, J. H., Lee, T., Olejniczak, E. T., & Fesik, S. W. (2018). Understanding the species selectivity of myeloid cell Leukemia-1 (Mcl-1) inhibitors. Biochemistry, 57(32), 4952–4958. doi:10.1021/acs.biochem.8b00626
   PubMed Web of Science ®Google Scholar